Paper Details
- Home
- Paper Details
Original Abstract of the Article :
The safety of ondansetron has been carefully evaluated through laboratory studies and clinical trials. Preclinical studies demonstrated that there is no end-organ toxicity in rats and dogs administered ondansetron doses 30 to 100 times those used in humans. At near-lethal doses of ondansetron, anima...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://pubmed.ncbi.nlm.nih.gov/1387251
データ提供：米国国立医学図書館（NLM）
Ondansetron: A Safe and Effective Anti-Emetic for Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) is a common and distressing side effect of cancer treatment. This review examines the safety and efficacy of ondansetron, a serotonin antagonist, as an anti-emetic for patients receiving chemotherapy. The authors provide a comprehensive overview of the preclinical and clinical evidence supporting the use of ondansetron in managing CINV.
Ondansetron: A Well-Tolerated Anti-Emetic
The review highlights the favorable safety profile of ondansetron, demonstrating its effectiveness in reducing CINV while minimizing adverse effects. Preclinical studies in animals revealed no significant end-organ toxicity, while clinical trials in both adult and pediatric patients showed ondansetron to be well-tolerated, with a lower incidence of side effects compared to other anti-emetics, such as metoclopramide. These findings provide strong support for the use of ondansetron as a safe and effective anti-emetic for patients undergoing chemotherapy.
Improving Quality of Life for Cancer Patients: The Role of Ondansetron
The review underscores the importance of effectively managing CINV to enhance the quality of life for cancer patients. By reducing nausea and vomiting, ondansetron can improve patients' well-being, allowing them to better tolerate chemotherapy and participate more fully in their treatment and recovery. This review highlights the significant role of ondansetron in improving the overall experience of cancer treatment for patients.
Dr.Camel's Conclusion
This review provides compelling evidence for the safety and efficacy of ondansetron as an anti-emetic for patients undergoing chemotherapy. The findings highlight the crucial role of ondansetron in improving the quality of life for cancer patients by effectively managing CINV and minimizing side effects. This research reaffirms the importance of developing and utilizing safe and effective anti-emetics to enhance the experience of cancer treatment and support patients throughout their journey.
Date :
- Date Completed 1992-09-18
- Date Revised 2018-05-24
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.